RMD - ResMed Inc Stock Price, Fair Value and News

184.98USD-0.88 (-0.47%)Market Closed

Market Summary

USD184.98-0.88

Market Closed

-0.47%

RMD Stock Price

View Fullscreen

RMD RSI Chart

RMD Valuation

Market Cap

27.2B

Price/Earnings (Trailing)

30.56

Price/Sales (Trailing)

6.04

EV/EBITDA

23.13

Price/Free Cashflow

28.27

RMD Price/Sales (Trailing)

RMD Profitability

EBT Margin

24.37%

Return on Equity

19.87%

Return on Assets

12.89%

Free Cashflow Yield

3.54%

RMD Fundamentals

RMD Revenue

Revenue (TTM)

4.5B

Rev. Growth (Yr)

12.48%

Rev. Growth (Qtr)

5.49%

RMD Earnings

Earnings (TTM)

890.4M

Earnings Growth (Yr)

-7.16%

Earnings Growth (Qtr)

-4.84%

Breaking Down RMD Revenue

Last 7 days

-1.5%

Last 30 days

-2.7%

Last 90 days

8.7%

Trailing 12 Months

-17.2%

How does RMD drawdown profile look like?

RMD Financial Health

Current Ratio

3.11

Debt/Equity

0.27

Debt/Cashflow

0.89

RMD Investor Care

Dividend Yield

0.99%

Dividend/Share (TTM)

1.84

Shares Dilution (1Y)

0.12%

Diluted EPS (TTM)

6.05

Historical Charts for Stock Metrics

Get all data in R, Python etc through our Historical Stock Data APIs

Net sales

Year	Q1	Q2	Q3	Q4
2023	4.0B	4.2B	4.4B	4.5B
2022	3.5B	3.6B	3.6B	3.8B
2021	3.1B	3.2B	3.3B	3.4B
2020	2.9B	3.0B	3.0B	3.1B
2019	2.5B	2.6B	2.7B	2.8B
2018	2.3B	2.3B	2.4B	2.5B
2017	2.0B	2.1B	2.1B	2.2B
2016	1.8B	1.8B	1.9B	2.0B
2015	1.6B	1.7B	1.7B	1.7B
2014	1.6B	1.6B	1.6B	1.6B
2013	1.5B	1.5B	1.5B	1.5B
2012	1.3B	1.4B	1.4B	1.4B
2011	1.2B	1.2B	1.3B	1.3B
2010	1.0B	1.1B	1.1B	1.2B
2009	0	920.7M	963.6M	1.0B

Get all data in R, Python etc through our Historical Stock Data APIs

GRUFITY'S FAIR VALUE MODEL

Stocks Marked 'Very Cheap' by Grufity's Fair Value Model Have Outperformed S&P 500 Index

Grufity's Fair Value model takes all the S&P 500 stocks and divides them into separate buckets based on their attractiveness. The 'Very Cheap' bucket of S&P 500 has greatly outperformed S&P 500 Index. Conversely, S&P500 stocks considered 'Very Expensive' by the model underperformed the S&P500 index in the past three years. Grufity Fair Value is available for 2300+ stocks, including 90% of S&P 500 stocks. Grufity's Fair Value Model separates high-return stocks from low-return stocks.

Returns of $10,000 invested in:

Very Cheap Stocks: $17,289
S&P 500 Index: $12,922
Very Expensive Stocks: $11,022

Grufity's Fair Value model does a great job in separating High Performing Stocks from Low Performing ones in the S&P 500 list.

S&P 500 Index

Very Expensive Stocks

Very Cheap Stocks

Try For Just $1.99

Tracking the Latest Insider Buys and Sells of ResMed Inc

Filter Transactions

Datesorted ascending	Name	Buy/Sell	$ Value	Avg. Price	# Shares	Title
Mar 04, 2024	rider michael j	sold	-14,580	180	-81.00	global general counsel
Mar 01, 2024	rider michael j	sold	-34,650	173	-200	global general counsel
Feb 22, 2024	farrell peter c	sold	-1,997,430	182	-10,935	-
Nov 27, 2023	sandercock brett	sold	-457,860	152	-3,000	chief financial officer
Nov 22, 2023	rider michael j	gifted	-	-	-72.00	global general counsel
Nov 20, 2023	douglas robert andrew	sold (taxes)	-204,825	148	-1,375	president and coo
Nov 20, 2023	farrell michael j.	sold (taxes)	-350,445	148	-2,352	chief executive officer
Nov 20, 2023	ghoshal kaushik	sold (taxes)	-54,656	148	-366	president, saas business
Nov 16, 2023	drexler karen	acquired	-	-	884	-

Which funds bought or sold RMD recently?

View All Details

Datesorted ascending	Fund Name	Type	% Chg	$ Change	$ Held	% Portfolio
Apr 12, 2024	CHANNEL WEALTH LLC	sold off	-100	-564,742	-	-%
Apr 12, 2024	AdvisorNet Financial, Inc	reduced	-2.68	4,639	43,171	-%
Apr 12, 2024	DNB Asset Management AS	reduced	-11.21	98,990	4,576,670	0.02%
Apr 12, 2024	BALDWIN BROTHERS LLC/MA	reduced	-6.08	124,209	1,652,570	0.12%
Apr 12, 2024	West Coast Financial LLC	reduced	-1.13	874,458	7,203,440	0.87%
Apr 12, 2024	Financial Synergies Wealth Advisors, Inc.	sold off	-100	-1,249	-	-%
Apr 12, 2024	Riverview Trust Co	new	-	41,586	41,586	0.03%
Apr 12, 2024	HARBOR INVESTMENT ADVISORY, LLC	unchanged	-	8,402	63,964	0.01%
Apr 12, 2024	GATEWAY INVESTMENT ADVISERS LLC	reduced	-0.81	102,873	827,765	0.01%
Apr 12, 2024	Pacifica Partners Inc.	unchanged	-	1,279	7,721	-%

Are Funds Buying or Selling RMD?

Are funds buying RMD calls or puts?

Calls

Puts

No. of funds holding Calls - Puts

Net Call Options

No. of funds that own RMD

No. of Funds

Unveiling ResMed Inc's Major ShareHolders

Date Filed	Name of Filer	Percent of Class	No. of Shares	Form Type
Feb 13, 2024	vanguard group inc	12.56%	18,478,846	SC 13G/A
Jan 25, 2024	blackrock inc.	8.7%	12,783,715	SC 13G/A
Feb 10, 2023	wcm investment management, llc	2.6%	3,832,642	SC 13G/A
Feb 09, 2023	vanguard group inc	11.63%	17,028,881	SC 13G/A
Feb 07, 2023	blackrock inc.	9.4%	13,774,787	SC 13G/A
Feb 10, 2022	vanguard group inc	11.06%	16,119,963	SC 13G/A
Feb 10, 2022	wcm investment management, llc	6.21%	9,046,150	SC 13G/A
Feb 01, 2022	blackrock inc.	9.3%	13,561,224	SC 13G/A
Feb 10, 2021	wcm investment management, llc	6.09%	8,821,570	SC 13G/A
Feb 10, 2021	vanguard group inc	10.65%	15,439,844	SC 13G/A

Recent SEC filings of ResMed Inc

View All Filings

Date Filed	Form Type	Document
Mar 06, 2024	4	Insider Trading
Mar 04, 2024	4	Insider Trading
Mar 04, 2024	144	Notice of Insider Sale Intent
Mar 01, 2024	144	Notice of Insider Sale Intent
Feb 23, 2024	4	Insider Trading
Feb 22, 2024	144	Notice of Insider Sale Intent
Feb 13, 2024	SC 13G/A	Major Ownership Report
Feb 06, 2024	144	Notice of Insider Sale Intent
Jan 25, 2024	SC 13G/A	Major Ownership Report
Jan 25, 2024	10-Q	Quarterly Report

Peers (Alternatives to ResMed Inc)

Name	Mkt Capsorted ascending	Revenue	Price %, 1M	Returns, 1Y	P/E	P/S	Rev 1-Yr	Inc 1-Yr
LARGE-CAP
ABT	188.9B	40.1B	-5.73%	4.72%	33.01	4.71	-8.12%	-17.45%
BDX	67.8B	19.5B	-0.88%	-8.17%	53.97	3.48	4.02%	-22.04%
ALGN	22.9B	3.9B	-3.10%	-11.00%	51.41	5.92	3.42%	23.09%
BAX	20.3B	14.8B	-3.77%	-6.99%	7.66	1.37	2.12%	209.17%
MID-CAP
ATR	9.1B	3.5B	-1.99%	15.94%	32.07	2.62	4.97%	18.89%
HSIC	9.1B	12.3B	-5.16%	-14.19%	21.85	0.74	-2.44%	-22.68%
BIO	8.8B	2.7B	-9.88%	-37.29%	-13.77	3.29	-4.68%	82.43%
XRAY	6.4B	4.0B	-5.94%	-24.93%	-47.62	1.62	1.10%	85.84%
AXNX	3.4B	366.4M	-0.71%	17.46%	-565.84	9.37	33.86%	89.83%
PDCO	2.3B	6.6B	-6.94%	-4.63%	11.73	0.35	2.78%	-0.87%
SMALL-CAP
AHCO	1.3B	3.2B	-3.79%	-17.24%	-1.94	0.41	7.73%	-1066.14%
ANIK	376.4M	166.7M	-0.35%	-8.55%	-4.55	2.26	6.67%	-456.34%
ANGO	253.5M	324.0M	17.88%	-30.36%	-1.32	0.78	-3.19%	-337.41%
APYX	47.8M	52.3M	-22.91%	-54.00%	-2.55	0.91	17.61%	19.28%
AEMD	3.8M	3.7M	-16.18%	262.50%	-0.31	1.01	5.77%	8.23%

ResMed Inc News

Latest updates

ResMed Inc Earnings Report: Key Takeaways & Analysis

Income Statement (Last 12 Months)

(In Millions)

(*) denotes actual numbers (not divided by Millions)
Income Statement (Quarterly)																					(In Millions)
Description	(%) Q/Q	2023Q4	2023Q3	2023Q2	2023Q1	2022Q4	2022Q3	2022Q2	2022Q1	2021Q4	2021Q3	2021Q2	2021Q1	2020Q4	2020Q3	2020Q2	2020Q1	2019Q4	2019Q3	2019Q2	2019Q1	2018Q4
Revenue	5.5%	1,163	1,102	1,122	1,117	1,034	950	915	865	895	904	876	769	800	752	770	769	736	681	705	662	651
Gross Profit	7.8%	647	600	617	618	580	541	523	491	504	506	491	447	462	439	449	450	427	392	399	381	375
Operating Expenses	19.5%	372	311	342	317	300	265	267	257	256	244	249	224	241	222	226	232	229	221	278	224	217
S&GA Expenses	-0.3%	222	223	240	228	212	194	193	182	185	177	181	160	169	159	165	172	171	167	172	165	162
R&D Expenses	-2.4%	74.00	76.00	78.00	76.00	70.00	63.00	64.00	67.00	63.00	60.00	60.00	56.00	55.00	55.00	53.00	51.00	50.00	48.00	51.00	48.00	43.00
EBITDA Margin	-3.7%	0.27*	0.28*	0.29*	0.29*	0.30*	0.30*	0.31*	0.30*	0.31*	0.31*	0.32*	0.31*	-	-	-	-	-	-	-	-	-
Interest Expenses	7.7%	-13.80	-14.96	-14.94	-14.96	-10.34	-7.13	-5.54	-5.46	-5.95	-5.36	-41.97	6.00	6.00	7.00	-70.54	10.00	10.00	11.00	13.00	12.00	7.00
Income Taxes	-4.0%	51.00	53.00	47.00	57.00	49.00	51.00	43.00	47.00	36.00	55.00	44.00	296	31.00	37.00	34.00	29.00	18.00	30.00	27.00	33.00	22.00
Earnings Before Taxes	-4.7%	259	272	277	289	274	262	238	226	237	259	239	218	211	216	212	192	179	151	96.00	138	146
EBT Margin	-4.1%	0.24*	0.25*	0.26*	0.26*	0.27*	0.27*	0.27*	0.27*	0.28*	0.28*	0.28*	0.28*	-	-	-	-	-	-	-	-	-
Net Income	-4.8%	209	219	230	233	225	210	195	179	202	204	195	-78.48	180	178	178	163	161	120	69.00	105	125
Net Income Margin	-4.6%	0.20*	0.21*	0.21*	0.21*	0.22*	0.22*	0.22*	0.22*	0.15*	0.15*	0.15*	0.15*	-	-	-	-	-	-	-	-	-
Free Cashflow	-2.6%	249	256	203	254	101	16.00	51.00	69.00	189	-93.00	199	170	-	-	-	-	-	-	-	-	-

Balance Sheet

(In Millions)

(*) denotes actual numbers (not divided by Millions)
Balance Sheet																					(In Millions)
Description	(%) Q/Q	2023Q4	2023Q3	2023Q2	2023Q1	2022Q4	2022Q3	2022Q2	2022Q1	2021Q4	2021Q3	2021Q2	2021Q1	2020Q4	2020Q3	2020Q2	2020Q1	2019Q4	2019Q3	2019Q2	2019Q1	2018Q4
Assets	2.4%	6,905	6,741	6,752	6,714	6,676	5,178	5,096	4,905	4,735	4,729	4,728	4,586	4,573	4,621	4,587	4,511	4,354	4,155	4,108	4,099	3,860
Current Assets	3.2%	2,378	2,305	2,368	2,338	2,325	2,034	1,931	1,704	1,547	1,586	1,575	1,466	1,451	1,543	1,523	1,470	1,300	1,161	1,145	1,103	1,064
Cash Equivalents	0.5%	210	209	228	228	253	207	274	202	194	276	295	231	256	421	463	353	204	172	147	147	149
Inventory	-2.6%	933	958	998	1,011	989	865	744	665	592	507	457	484	475	478	417	359	378	357	350	320	297
Net PPE	3.3%	552	534	538	529	523	487	498	513	478	467	463	455	459	425	417	397	408	383	387	382	382
Goodwill	1.8%	2,862	2,812	2,770	2,784	2,767	1,939	1,936	1,946	1,951	1,922	1,928	1,926	1,910	1,900	1,890	1,884	1,871	1,856	1,856	1,939	1,759
Liabilities	-2.7%	2,423	2,490	2,622	2,781	2,938	1,745	1,735	1,626	1,589	1,703	1,842	1,876	1,708	1,942	2,090	2,254	2,096	2,037	2,035	2,077	1,904
Current Liabilities	-0.9%	764	771	759	762	733	693	689	667	621	624	912	877	577	591	603	552	500	550	556	463	436
Short Term Borrowings	-0.1%	10.00	10.00	10.00	10.00	10.00	10.00	10.00	12.00	12.00	12.00	12.00	12.00	12.00	12.00	12.00	12.00	12.00	12.00	12.00	12.00	12.00
Long Term Debt	-10.0%	1,217	1,352	1,431	1,576	1,791	785	765	669	668	794	643	719	814	1,044	1,164	1,365	1,288	1,208	1,259	1,323	1,186
Shareholder's Equity	5.4%	4,482	4,250	4,130	3,933	3,738	3,433	3,361	3,279	3,146	3,026	2,886	2,709	2,865	2,679	2,497	2,256	2,258	2,117	2,072	2,021	1,956
Retained Earnings	3.1%	4,540	4,402	4,253	4,088	3,920	3,760	3,614	3,480	3,363	3,222	3,080	2,941	3,077	2,954	2,833	2,712	2,605	2,501	2,436	2,421	2,368
Additional Paid-In Capital	1.8%	1,823	1,791	1,772	1,729	1,711	1,702	1,682	1,645	1,629	1,644	1,622	1,587	1,574	1,588	1,571	1,534	1,522	1,530	1,511	1,476	1,461
Shares Outstanding	0.0%	147	147	147	147	147	146	146	146	146	146	145	145	-	-	-	-	-	-	-	-	-
Float	-	-	-	-	-	30,201	-	-	-	37,771	-	-	-	30,662	-	-	-	22,240	-	-	-	16,204

Cashflow (Last 12 Months)

(In Millions)

(*) denotes actual numbers (not divided by Millions)
Cashflow (Quarterly)																					(In Millions)
Description	(%) Q/Q	2023Q4	2023Q3	2023Q2	2023Q1	2022Q4	2022Q3	2022Q2	2022Q1	2021Q4	2021Q3	2021Q2	2021Q1	2020Q4	2020Q3	2020Q2	2020Q1	2019Q4	2019Q3	2019Q2	2019Q1	2018Q4
Cashflow From Operations	-4.7%	273	286	237	283	129	45.00	79.00	117	220	-65.66	227	196	170	144	330	240	70.00	162	142	140	129
Share Based Compensation	7.2%	20.00	19.00	20.00	18.00	16.00	17.00	16.00	16.00	16.00	17.00	17.00	16.00	15.00	16.00	16.00	14.00	14.00	13.00	14.00	13.00	13.00
Cashflow From Investing	72.4%	-41.14	-148	-46.52	-28.10	-1,026	-58.81	-55.24	-49.49	-83.31	-41.87	-48.07	-58.62	-29.66	-22.11	-3.41	-99.61	-43.62	-33.22	-43.89	-225	-658
Cashflow From Financing	-58.1%	-238	-151	-188	-279	933	-41.88	57.00	-60.86	-217	93.00	-114	-158	-316	-175	-236	18.00	1.00	-100	-97.57	83.00	450
Dividend Payments	0.1%	71.00	71.00	65.00	65.00	65.00	64.00	61.00	61.00	61.00	61.00	57.00	57.00	57.00	57.00	56.00	56.00	56.00	56.00	53.00	53.00	53.00
Buy Backs	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	3.00

RMD Income Statement

2023-12-31

Condensed Consolidated Statements of Operations (Unaudited) - USD ($) shares in Thousands, $ in Thousands	3 Months Ended		6 Months Ended
	Dec. 31, 2023	Dec. 31, 2022	Dec. 31, 2023	Dec. 31, 2022
Net revenue	$ 1,162,801	$ 1,033,744	$ 2,265,122	$ 1,984,038
Cost of sales (exclusive of amortization shown separately below)	507,610	446,724	1,000,964	849,834
Amortization of acquired intangible assets	8,257	7,305	17,164	13,680
Total cost of sales	515,867	454,029	1,018,128	863,514
Gross profit	646,934	579,715	1,246,994	1,120,524
Operating Expenses
Selling, general, and administrative	222,155	211,672	445,029	404,860
Research and development	73,880	69,874	149,590	133,062
Amortization of acquired intangible assets	11,577	9,563	24,056	17,513
Restructuring expenses (note 11)	64,228	0	64,228	0
Acquisition related expenses	0	8,412	0	9,157
Total operating expenses	371,840	299,521	682,903	564,592
Income from operations	275,094	280,194	564,091	555,932
Other income (loss), net:
Interest (expense) income, net	(13,805)	(10,338)	(28,762)	(17,472)
Gain (loss) attributable to equity method investments (note 5)	739	(2,826)	(3,156)	(4,853)
Gain (loss) on equity investments (note 5)	(1,888)	8,368	(2,491)	5,088
Other, net	(686)	(1,707)	1,963	(3,211)
Total other income (loss), net	(15,640)	(6,503)	(32,446)	(20,448)
Income before income taxes	259,454	273,691	531,645	535,484
Income taxes	50,654	48,777	103,423	100,092
Net income	$ 208,800	$ 224,914	$ 428,222	$ 435,392
Basic earnings per share (in dollars per share)	$ 1.42	$ 1.53	$ 2.91	$ 2.97
Diluted earnings per share (in dollars per share)	1.42	1.53	2.90	2.95
Dividend declared per share (in dollars per share)	$ 0.48	$ 0.44	$ 0.96	$ 0.88
Basic shares outstanding (000's) (in shares)	147,132	146,704	147,104	146,568
Diluted shares outstanding (000's) (in shares)	147,545	147,405	147,572	147,367
Total Sleep and Respiratory Care
Net revenue	$ 1,017,855	$ 916,981	$ 1,980,892	$ 1,761,424
Cost of sales (exclusive of amortization shown separately below)	460,721	406,303	905,182	770,146
Amortization of acquired intangible assets	1,324	1,343	3,240	2,572
Software as a Service
Net revenue	144,946	116,763	284,230	222,614
Cost of sales (exclusive of amortization shown separately below)	46,889	40,421	95,782	79,688
Amortization of acquired intangible assets	$ 6,933	$ 5,962	$ 13,924	$ 11,108

RMD Balance Sheet

2023-12-31

Condensed Consolidated Balance Sheets (Unaudited) - USD ($) $ in Thousands	Dec. 31, 2023	Jun. 30, 2023
Current assets:
Cash and cash equivalents	$ 210,247	$ 227,891
Accounts receivable, net of allowances of $21,822 and $23,603 at December 31, 2023 and June 30, 2023, respectively	729,740	704,909
Inventories (note 3)	933,214	998,012
Prepaid expenses and other current assets (note 3)	504,876	437,018
Total current assets	2,378,077	2,367,830
Non-current assets:
Property, plant and equipment, net (note 3)	551,734	537,856
Operating lease right-of-use assets	153,473	127,955
Goodwill (note 4)	2,861,854	2,770,299
Other intangible assets, net (note 3)	528,178	552,341
Deferred income taxes	155,955	132,974
Prepaid taxes and other non-current assets	275,817	262,453
Total non-current assets	4,527,011	4,383,878
Total assets	6,905,088	6,751,708
Current liabilities:
Accounts payable	202,395	150,756
Accrued expenses	332,136	365,660
Operating lease liabilities, current	24,057	21,919
Deferred revenue	148,897	138,072
Income taxes payable	46,690	72,224
Short-term debt, net (note 7)	9,898	9,902
Total current liabilities	764,073	758,533
Non-current liabilities:
Deferred revenue	127,410	119,186
Deferred income taxes	89,282	90,650
Operating lease liabilities, non-current	140,649	116,853
Other long-term liabilities	72,894	68,166
Long-term debt, net (note 7)	1,216,769	1,431,234
Long-term income taxes payable	12,157	37,183
Total non-current liabilities	1,659,161	1,863,272
Total liabilities	2,423,234	2,621,805
Commitments and contingencies (note 9)
Stockholders’ equity:
Preferred stock, $0.01 par value, 2,000,000 shares authorized; none issued	0	0
Common stock, $0.004 par value, 350,000,000 shares authorized; 189,259,220 issued and 147,087,512 outstanding at December 31, 2023 and 188,900,583 issued and 147,064,349 outstanding at June 30, 2023	588	588
Additional paid-in capital	1,822,918	1,772,083
Retained earnings	4,539,963	4,253,016
Treasury stock, at cost, 42,171,708 shares at December 31, 2023 and 41,836,234 shares at June 30, 2023	(1,673,263)	(1,623,256)
Accumulated other comprehensive loss	(208,352)	(272,528)
Total stockholders’ equity	4,481,854	4,129,903
Total liabilities and stockholders’ equity	$ 6,905,088	$ 6,751,708

About ResMed Inc

ResMed Inc. develops, manufactures, distributes, and markets medical devices and cloud-based software applications for the healthcare markets. It operates in two segments, Sleep and Respiratory Care, and Software as a Service. It offers various products and solutions for a range of respiratory disorders, including technologies to be applied in medical and consumer products, ventilation devices, diagnostic products, mask systems for use in the hospital and home, headgear and other accessories, dental devices, and cloud-based software informatics solutions to manage patient outcomes, as well as provides customer and business processes. The company also provides AirView, a cloud-based system that enables remote monitoring and changing of patients' device settings; myAir, a personalized therapy management application for patients with sleep apnea that provides support, education, and troubleshooting tools for increased patient engagement and improved compliance; U-Sleep, a compliance monitoring solution that enables home medical equipment (HME) to streamline their sleep programs; connectivity module and propeller solutions; and Propeller portal. It offers out-of-hospital software solution, such as Brightree business management software and service solutions to providers of HME, pharmacy, home infusion, orthotics, and prosthetics services; MatrixCare care management and related ancillary solutions to senior living, skilled nursing, life plan communities, home health, home care, and hospice organizations, as well as related accountable care organizations; HEALTHCAREfirst that offers electronic health record, software, billing and coding services, and analytics for home health and hospice agencies; and MEDIFOX DAN's software solutions. The company markets its products to sleep clinics, home healthcare dealers, and hospitals through a network of distributors and direct sales force. The company was founded in 1989 and is headquartered in San Diego, California.

CEO	Mr. Michael J. Farrell BE, MBA, SM
WEBSITE	resmed.com
INDUSTRY	Medical Instruments & Supplies
EMPLOYEES	10140

ResMed Inc Frequently Asked Questions

What is the ticker symbol for ResMed Inc? What does RMD stand for in stocks?

RMD is the stock ticker symbol of ResMed Inc. Every public company that trades on a stock exchange gets a ticker symbol.

What is the market capital of ResMed Inc (RMD)?

As of Mon Apr 15 2024, market cap of ResMed Inc is 27.21 Billion. The market capitalization is calculated by multiplying the stock price with the number of shares outstanding.

What is the fair value of RMD stock?

You can check RMD's fair value in chart for subscribers.

What is the fair value of RMD stock?

You can check RMD's fair value in chart for subscribers. The fair value of ResMed Inc is provided for various growth and macro-economic scenarios from very pessimiatic to very optimistic assumptions. These fair values are estimates from Grufity's Fair Value model based on company's past performance. However, past performance of ResMed Inc is no guarantee of future performance. These fairvalue estimates should only be used as one of the inputs in your stock analysis. We provide model's historical fair value estimates for RMD so that you know how good or bad the model has been in the past so you can discard it if needed. There are others that provide fair values of stocks such as wallmine, finbox, gurufocus and finviz. Most provide point in time estimates. We provide a history of our models fair value estimates so that you can get a sense of it's usefulness. Otherwise this data point is of little use.

Is ResMed Inc a good stock to buy?

The fair value guage provides a quick view whether RMD is over valued or under valued. Whether ResMed Inc is cheap or expensive depends on the assumptions which impact ResMed Inc's fair value. We provide several scenarios of inflation and growth to encompass these range of assumptions for RMD.

What is ResMed Inc's Price to Earnings (PE) and Price to sales (PS) ratio?

As of Mon Apr 15 2024, RMD's PE ratio (Price to Earnings) is 30.56 and Price to Sales (PS) ratio is 6.04. The price to earnings and price to sales ratio are two most important valuation metrics for any company. PE ratio tell us the number of years of earnings investors are ready to pay for owning the company. Historically, S&P500 price to earnings ratio has fallen below 12 during periods of gloom and gone past 30 during periods of euphoria. RMD PE ratio will change depending on the future growth rate expectations of investors.

What is 5 year return on ResMed Inc's stock?

In the past 10 years, ResMed Inc has provided 0.161 (multiply by 100 for percentage) rate of return.